Oxyphenbutazone
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.004.489 |
Chemical and physical data | |
Formula | C19H20N2O3 |
Molar mass | 324.379 g/mol |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID).[1] It is a metabolite of phenylbutazone.[2]
It was withdrawn from markets worldwide in mid-1980s due to bone marrow suppression and Stevens–Johnson syndrome.[3][4]
References
- ↑ Singh, N.; Jabeen, T.; Somvanshi, R. K.; Sharma, S.; Dey, S.; Singh, T. P. (2004). "Phospholipase A2as a Target Protein for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Crystal Structure of the Complex Formed between Phospholipase A2and Oxyphenbutazone at 1.6 Å Resolution†". Biochemistry. 43 (46): 14577–14583. PMID 15544328. doi:10.1021/bi0483561.
- ↑ Matthews, N. S.; Peck, K. E.; Taylor, T. S.; Mealey, K. L. (2001). "Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys". American journal of veterinary research. 62 (5): 673–675. PMID 11341383.
- ↑ Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134.
- ↑ Biron, P (15 May 1986). "Withdrawal of oxyphenbutazone: what about phenylbutazone?". CMAJ : Canadian Medical Association journal [Journal de l'Association medicale canadienne]. 134 (10): 1119–20. PMC 1491052 . PMID 3697857.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.